GRAIL, Inc. (NASDAQ:GRAL) Receives $67.88 Consensus Price Target from Analysts

Shares of GRAIL, Inc. (NASDAQ:GRAL) have received a consensus recommendation of “Hold” from the ten research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $67.00.

Several brokerages have weighed in on GRAL. Mizuho began coverage on GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective for the company. The Goldman Sachs Group began coverage on GRAIL in a report on Friday. They set a “neutral” rating and a $60.00 price objective for the company. Piper Sandler boosted their price objective on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st.

GRAIL Stock Down 9.9%

Shares of NASDAQ GRAL opened at $59.98 on Friday. The firm’s 50-day simple moving average is $57.27 and its 200 day simple moving average is $75.49. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -5.78 and a beta of 3.15. GRAIL has a 12-month low of $29.95 and a 12-month high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.79 million for the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. On average, equities analysts expect that GRAIL will post -10.99 earnings per share for the current year.

Insider Transactions at GRAIL

In other GRAIL news, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer directly owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 245,354 shares of company stock valued at $12,238,545. 1.83% of the stock is owned by company insiders.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Perigon Wealth Management LLC increased its stake in shares of GRAIL by 0.7% in the 4th quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock valued at $1,665,000 after acquiring an additional 133 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of GRAIL by 5.2% in the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock valued at $228,000 after acquiring an additional 133 shares during the last quarter. Westmount Partners LLC increased its stake in shares of GRAIL by 1.8% in the 4th quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock valued at $709,000 after acquiring an additional 150 shares during the last quarter. Comerica Bank increased its stake in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares during the last quarter. Finally, Whittier Trust Co. increased its stake in shares of GRAIL by 19.3% in the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock valued at $95,000 after acquiring an additional 180 shares during the last quarter.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.